Plasma Levels of Parathyroid Hormone (1–84) Whole Molecule and Parathyroid Hormone (7–84)-Like Fragments in Pseudohypoparathyroidism Type I
PTH (7–84) has antagonistic effects on the calcemic and phosphaturic actions of PTH (1–84) whole molecule (bioPTH). Human plasma contains bioPTH and PTH (7–84)-like fragments. Using bioPTH-specific and nonspecific assays, we found that the patients with pseudohypoparathyroidism (PHP) type I with PTH...
Gespeichert in:
Veröffentlicht in: | The journal of clinical endocrinology and metabolism 2003-05, Vol.88 (5), p.2250-2255 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2255 |
---|---|
container_issue | 5 |
container_start_page | 2250 |
container_title | The journal of clinical endocrinology and metabolism |
container_volume | 88 |
creator | Hatakeyama, Yuriko Mizunashi, Kazutoshi Furukawa, Yohtaro Yabuki, Shigemitsu Sato, Yumi Igarashi, Teruo |
description | PTH (7–84) has antagonistic effects on the calcemic and phosphaturic actions of PTH (1–84) whole molecule (bioPTH). Human plasma contains bioPTH and PTH (7–84)-like fragments. Using bioPTH-specific and nonspecific assays, we found that the patients with pseudohypoparathyroidism (PHP) type I with PTH-resistant hypocalcemia and hyperphosphatemia had the increased plasma levels of bioPTH and PTH (7–84)-like fragments than normal subjects (26.8 ± 13.2 vs. 2.37 ± 0.75 pmol/liter, P < 0.01 and 16.2 ± 8.8 vs. 0.82 ± 0.47 pmol/liter, P < 0.01, respectively). Calcitriol treatment increased phosphaturic response to PTH (1–34) (P < 0.05), and there was a negative correlation between phosphaturic response and the PTH levels (P < 0.05). These results suggested that the increased bioPTH and PTH (7–84)-like fragment levels may be related to the impaired phosphaturic response to PTH (1–34) in PHP type I. We also examined bioPTH-calcium dynamics in PHP type Ib patients and found that set-point calcium was 0.928 ± 0.045 mmol/liter and the baseline to maximal ratio of bioPTH was 0.96 ± 0.04. Calcitriol treatment increased set-point calcium to 1.129 ± 0.028 mmol/liter (P < 0.01) and suppressed baseline to maximal ratio of bioPTH to 0.35 ± 0.21 (P < 0.01). These bio-PTH calcium dynamics studies revealed the maximally stimulated baseline PTH secretion in PHP type Ib and demonstrated the effects of calcitriol on PTH-calcium curve shift and the degree of relative stimulation of baseline secretion. |
doi_str_mv | 10.1210/jc.2002-021610 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73239153</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73239153</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5181-c54c0bfe89f4a953fb774f9862339a15f256db449f9fc7793e3ad8f61297b2723</originalsourceid><addsrcrecordid>eNp1kc9u1DAQxi0EokvhyhH5AoJDFv9dx0dUUVppEXsogpvlOGOSbRIHO6HaG2_AgTfkSXCVlfYCljxjy79vbM-H0HNK1pRR8nbv1owQVhBGN5Q8QCuqhSwU1eohWuUDWmjFvp6hJyntCaFCSP4YnVGmmNIlW6Ffu86m3uIt_IAu4eDxzkY7NYcY2hpfhdiHAfBr-ufn71K8wV-a0AH-mIOb88IO9b95tfDFtr0FfBnttx6GKeF2wLsEcx2awxjGk7BNPb45jICvn6JH3nYJnh3zOfp8-f7m4qrYfvpwffFuWzhJS5qjcKTyUGovrJbcV0oJr8sN41xbKj2Tm7oSQnvtnVKaA7d16TeUaVXlz_Nz9GqpO8bwfYY0mb5NDrrODhDmZBRnXFPJM7heQBdDShG8GWPb23gwlJh7C8zemXsLzGJBFrw4Vp6rHuoTfux5Bl4eAZuc7Xy0g2vTiRMlEYSqzImFuwvdBDHddvMdRNOA7abGkDzERpVFvpsTmXdFnpJmmVxkMNTBxXaAMUJKZh_mOOSW_u_dfwFziLED</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73239153</pqid></control><display><type>article</type><title>Plasma Levels of Parathyroid Hormone (1–84) Whole Molecule and Parathyroid Hormone (7–84)-Like Fragments in Pseudohypoparathyroidism Type I</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Hatakeyama, Yuriko ; Mizunashi, Kazutoshi ; Furukawa, Yohtaro ; Yabuki, Shigemitsu ; Sato, Yumi ; Igarashi, Teruo</creator><creatorcontrib>Hatakeyama, Yuriko ; Mizunashi, Kazutoshi ; Furukawa, Yohtaro ; Yabuki, Shigemitsu ; Sato, Yumi ; Igarashi, Teruo</creatorcontrib><description><![CDATA[PTH (7–84) has antagonistic effects on the calcemic and phosphaturic actions of PTH (1–84) whole molecule (bioPTH). Human plasma contains bioPTH and PTH (7–84)-like fragments. Using bioPTH-specific and nonspecific assays, we found that the patients with pseudohypoparathyroidism (PHP) type I with PTH-resistant hypocalcemia and hyperphosphatemia had the increased plasma levels of bioPTH and PTH (7–84)-like fragments than normal subjects (26.8 ± 13.2 vs. 2.37 ± 0.75 pmol/liter, P < 0.01 and 16.2 ± 8.8 vs. 0.82 ± 0.47 pmol/liter, P < 0.01, respectively). Calcitriol treatment increased phosphaturic response to PTH (1–34) (P < 0.05), and there was a negative correlation between phosphaturic response and the PTH levels (P < 0.05). These results suggested that the increased bioPTH and PTH (7–84)-like fragment levels may be related to the impaired phosphaturic response to PTH (1–34) in PHP type I. We also examined bioPTH-calcium dynamics in PHP type Ib patients and found that set-point calcium was 0.928 ± 0.045 mmol/liter and the baseline to maximal ratio of bioPTH was 0.96 ± 0.04. Calcitriol treatment increased set-point calcium to 1.129 ± 0.028 mmol/liter (P < 0.01) and suppressed baseline to maximal ratio of bioPTH to 0.35 ± 0.21 (P < 0.01). These bio-PTH calcium dynamics studies revealed the maximally stimulated baseline PTH secretion in PHP type Ib and demonstrated the effects of calcitriol on PTH-calcium curve shift and the degree of relative stimulation of baseline secretion.]]></description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.2002-021610</identifier><identifier>PMID: 12727982</identifier><identifier>CODEN: JCEMAZ</identifier><language>eng</language><publisher>Bethesda, MD: Endocrine Society</publisher><subject>Adolescent ; Biological and medical sciences ; Calcitriol - administration & dosage ; Calcium - blood ; Drug Resistance ; Endocrinopathies ; Female ; Humans ; Hypocalcemia - drug therapy ; Hypocalcemia - etiology ; Male ; Medical sciences ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Parathyroid Hormone - administration & dosage ; Parathyroid Hormone - blood ; Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases) ; Peptide Fragments - administration & dosage ; Peptide Fragments - blood ; Phosphates - blood ; Phosphates - urine ; Pseudohypoparathyroidism - blood ; Pseudohypoparathyroidism - complications ; Reference Values</subject><ispartof>The journal of clinical endocrinology and metabolism, 2003-05, Vol.88 (5), p.2250-2255</ispartof><rights>Copyright © 2003 by The Endocrine Society</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5181-c54c0bfe89f4a953fb774f9862339a15f256db449f9fc7793e3ad8f61297b2723</citedby><cites>FETCH-LOGICAL-c5181-c54c0bfe89f4a953fb774f9862339a15f256db449f9fc7793e3ad8f61297b2723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14804017$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12727982$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hatakeyama, Yuriko</creatorcontrib><creatorcontrib>Mizunashi, Kazutoshi</creatorcontrib><creatorcontrib>Furukawa, Yohtaro</creatorcontrib><creatorcontrib>Yabuki, Shigemitsu</creatorcontrib><creatorcontrib>Sato, Yumi</creatorcontrib><creatorcontrib>Igarashi, Teruo</creatorcontrib><title>Plasma Levels of Parathyroid Hormone (1–84) Whole Molecule and Parathyroid Hormone (7–84)-Like Fragments in Pseudohypoparathyroidism Type I</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description><![CDATA[PTH (7–84) has antagonistic effects on the calcemic and phosphaturic actions of PTH (1–84) whole molecule (bioPTH). Human plasma contains bioPTH and PTH (7–84)-like fragments. Using bioPTH-specific and nonspecific assays, we found that the patients with pseudohypoparathyroidism (PHP) type I with PTH-resistant hypocalcemia and hyperphosphatemia had the increased plasma levels of bioPTH and PTH (7–84)-like fragments than normal subjects (26.8 ± 13.2 vs. 2.37 ± 0.75 pmol/liter, P < 0.01 and 16.2 ± 8.8 vs. 0.82 ± 0.47 pmol/liter, P < 0.01, respectively). Calcitriol treatment increased phosphaturic response to PTH (1–34) (P < 0.05), and there was a negative correlation between phosphaturic response and the PTH levels (P < 0.05). These results suggested that the increased bioPTH and PTH (7–84)-like fragment levels may be related to the impaired phosphaturic response to PTH (1–34) in PHP type I. We also examined bioPTH-calcium dynamics in PHP type Ib patients and found that set-point calcium was 0.928 ± 0.045 mmol/liter and the baseline to maximal ratio of bioPTH was 0.96 ± 0.04. Calcitriol treatment increased set-point calcium to 1.129 ± 0.028 mmol/liter (P < 0.01) and suppressed baseline to maximal ratio of bioPTH to 0.35 ± 0.21 (P < 0.01). These bio-PTH calcium dynamics studies revealed the maximally stimulated baseline PTH secretion in PHP type Ib and demonstrated the effects of calcitriol on PTH-calcium curve shift and the degree of relative stimulation of baseline secretion.]]></description><subject>Adolescent</subject><subject>Biological and medical sciences</subject><subject>Calcitriol - administration & dosage</subject><subject>Calcium - blood</subject><subject>Drug Resistance</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Humans</subject><subject>Hypocalcemia - drug therapy</subject><subject>Hypocalcemia - etiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>Parathyroid Hormone - administration & dosage</subject><subject>Parathyroid Hormone - blood</subject><subject>Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases)</subject><subject>Peptide Fragments - administration & dosage</subject><subject>Peptide Fragments - blood</subject><subject>Phosphates - blood</subject><subject>Phosphates - urine</subject><subject>Pseudohypoparathyroidism - blood</subject><subject>Pseudohypoparathyroidism - complications</subject><subject>Reference Values</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9u1DAQxi0EokvhyhH5AoJDFv9dx0dUUVppEXsogpvlOGOSbRIHO6HaG2_AgTfkSXCVlfYCljxjy79vbM-H0HNK1pRR8nbv1owQVhBGN5Q8QCuqhSwU1eohWuUDWmjFvp6hJyntCaFCSP4YnVGmmNIlW6Ffu86m3uIt_IAu4eDxzkY7NYcY2hpfhdiHAfBr-ufn71K8wV-a0AH-mIOb88IO9b95tfDFtr0FfBnttx6GKeF2wLsEcx2awxjGk7BNPb45jICvn6JH3nYJnh3zOfp8-f7m4qrYfvpwffFuWzhJS5qjcKTyUGovrJbcV0oJr8sN41xbKj2Tm7oSQnvtnVKaA7d16TeUaVXlz_Nz9GqpO8bwfYY0mb5NDrrODhDmZBRnXFPJM7heQBdDShG8GWPb23gwlJh7C8zemXsLzGJBFrw4Vp6rHuoTfux5Bl4eAZuc7Xy0g2vTiRMlEYSqzImFuwvdBDHddvMdRNOA7abGkDzERpVFvpsTmXdFnpJmmVxkMNTBxXaAMUJKZh_mOOSW_u_dfwFziLED</recordid><startdate>200305</startdate><enddate>200305</enddate><creator>Hatakeyama, Yuriko</creator><creator>Mizunashi, Kazutoshi</creator><creator>Furukawa, Yohtaro</creator><creator>Yabuki, Shigemitsu</creator><creator>Sato, Yumi</creator><creator>Igarashi, Teruo</creator><general>Endocrine Society</general><general>Copyright by The Endocrine Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200305</creationdate><title>Plasma Levels of Parathyroid Hormone (1–84) Whole Molecule and Parathyroid Hormone (7–84)-Like Fragments in Pseudohypoparathyroidism Type I</title><author>Hatakeyama, Yuriko ; Mizunashi, Kazutoshi ; Furukawa, Yohtaro ; Yabuki, Shigemitsu ; Sato, Yumi ; Igarashi, Teruo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5181-c54c0bfe89f4a953fb774f9862339a15f256db449f9fc7793e3ad8f61297b2723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Biological and medical sciences</topic><topic>Calcitriol - administration & dosage</topic><topic>Calcium - blood</topic><topic>Drug Resistance</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Humans</topic><topic>Hypocalcemia - drug therapy</topic><topic>Hypocalcemia - etiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>Parathyroid Hormone - administration & dosage</topic><topic>Parathyroid Hormone - blood</topic><topic>Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases)</topic><topic>Peptide Fragments - administration & dosage</topic><topic>Peptide Fragments - blood</topic><topic>Phosphates - blood</topic><topic>Phosphates - urine</topic><topic>Pseudohypoparathyroidism - blood</topic><topic>Pseudohypoparathyroidism - complications</topic><topic>Reference Values</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hatakeyama, Yuriko</creatorcontrib><creatorcontrib>Mizunashi, Kazutoshi</creatorcontrib><creatorcontrib>Furukawa, Yohtaro</creatorcontrib><creatorcontrib>Yabuki, Shigemitsu</creatorcontrib><creatorcontrib>Sato, Yumi</creatorcontrib><creatorcontrib>Igarashi, Teruo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hatakeyama, Yuriko</au><au>Mizunashi, Kazutoshi</au><au>Furukawa, Yohtaro</au><au>Yabuki, Shigemitsu</au><au>Sato, Yumi</au><au>Igarashi, Teruo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma Levels of Parathyroid Hormone (1–84) Whole Molecule and Parathyroid Hormone (7–84)-Like Fragments in Pseudohypoparathyroidism Type I</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2003-05</date><risdate>2003</risdate><volume>88</volume><issue>5</issue><spage>2250</spage><epage>2255</epage><pages>2250-2255</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><coden>JCEMAZ</coden><abstract><![CDATA[PTH (7–84) has antagonistic effects on the calcemic and phosphaturic actions of PTH (1–84) whole molecule (bioPTH). Human plasma contains bioPTH and PTH (7–84)-like fragments. Using bioPTH-specific and nonspecific assays, we found that the patients with pseudohypoparathyroidism (PHP) type I with PTH-resistant hypocalcemia and hyperphosphatemia had the increased plasma levels of bioPTH and PTH (7–84)-like fragments than normal subjects (26.8 ± 13.2 vs. 2.37 ± 0.75 pmol/liter, P < 0.01 and 16.2 ± 8.8 vs. 0.82 ± 0.47 pmol/liter, P < 0.01, respectively). Calcitriol treatment increased phosphaturic response to PTH (1–34) (P < 0.05), and there was a negative correlation between phosphaturic response and the PTH levels (P < 0.05). These results suggested that the increased bioPTH and PTH (7–84)-like fragment levels may be related to the impaired phosphaturic response to PTH (1–34) in PHP type I. We also examined bioPTH-calcium dynamics in PHP type Ib patients and found that set-point calcium was 0.928 ± 0.045 mmol/liter and the baseline to maximal ratio of bioPTH was 0.96 ± 0.04. Calcitriol treatment increased set-point calcium to 1.129 ± 0.028 mmol/liter (P < 0.01) and suppressed baseline to maximal ratio of bioPTH to 0.35 ± 0.21 (P < 0.01). These bio-PTH calcium dynamics studies revealed the maximally stimulated baseline PTH secretion in PHP type Ib and demonstrated the effects of calcitriol on PTH-calcium curve shift and the degree of relative stimulation of baseline secretion.]]></abstract><cop>Bethesda, MD</cop><pub>Endocrine Society</pub><pmid>12727982</pmid><doi>10.1210/jc.2002-021610</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-972X |
ispartof | The journal of clinical endocrinology and metabolism, 2003-05, Vol.88 (5), p.2250-2255 |
issn | 0021-972X 1945-7197 |
language | eng |
recordid | cdi_proquest_miscellaneous_73239153 |
source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals |
subjects | Adolescent Biological and medical sciences Calcitriol - administration & dosage Calcium - blood Drug Resistance Endocrinopathies Female Humans Hypocalcemia - drug therapy Hypocalcemia - etiology Male Medical sciences Non tumoral diseases. Target tissue resistance. Benign neoplasms Parathyroid Hormone - administration & dosage Parathyroid Hormone - blood Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases) Peptide Fragments - administration & dosage Peptide Fragments - blood Phosphates - blood Phosphates - urine Pseudohypoparathyroidism - blood Pseudohypoparathyroidism - complications Reference Values |
title | Plasma Levels of Parathyroid Hormone (1–84) Whole Molecule and Parathyroid Hormone (7–84)-Like Fragments in Pseudohypoparathyroidism Type I |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T03%3A45%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20Levels%20of%20Parathyroid%20Hormone%20(1%E2%80%9384)%20Whole%20Molecule%20and%20Parathyroid%20Hormone%20(7%E2%80%9384)-Like%20Fragments%20in%20Pseudohypoparathyroidism%20Type%20I&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Hatakeyama,%20Yuriko&rft.date=2003-05&rft.volume=88&rft.issue=5&rft.spage=2250&rft.epage=2255&rft.pages=2250-2255&rft.issn=0021-972X&rft.eissn=1945-7197&rft.coden=JCEMAZ&rft_id=info:doi/10.1210/jc.2002-021610&rft_dat=%3Cproquest_cross%3E73239153%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73239153&rft_id=info:pmid/12727982&rfr_iscdi=true |